{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:39:05Z","timestamp":1787071145441,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Cutaneous leishmaniasis (CL) is an ulcerative skin disease caused by some species of the genus\n                      <jats:italic toggle=\"yes\">Leishmania<\/jats:italic>\n                      . Evidence shows that\n                      <jats:italic toggle=\"yes\">Perovskia abrotanoides<\/jats:italic>\n                      is an important herbal medicine against\n                      <jats:italic toggle=\"yes\">Leishmania.<\/jats:italic>\n                      This study was conducted to investigate the killing effect of terpenoid-rich fractions on promastigotes of\n                      <jats:italic toggle=\"yes\">L. major<\/jats:italic>\n                      (MRHO\/IR\/75\/ER).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Method:<\/jats:title>\n                    <jats:p>\n                      The eluates of reverse phased medium pressure liquid chromatography (RP-MPLC) of the extract were subjected to thin-layer chromatography (TLC) and categorized into six final fractions. Primary proton nuclear magnetic resonance (H-NMR) spectroscopy confirmed fractions' nature. Fractions 4, 5, and 6 (F4, F5, F6) were identified as terpenoid-rich content. Two concentrations of 50 and 100 \u03bcg\/ml were prepared to test leishmanicidal activity. Followed by treating promastigotes of\n                      <jats:italic toggle=\"yes\">L. major<\/jats:italic>\n                      by the fractions in incubation times of 12, 24, and 48 hours, their viability was determined using a cell proliferation MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>\n                      F4, F5, and F6 showed significant killing activity on promastigotes of\n                      <jats:italic toggle=\"yes\">L. major<\/jats:italic>\n                      in a concentration-dependent manner. The viability of promastigotes was significantly reduced at a concentration of 100 \u03bcg\/ml compared to 50 \u03bcg\/ml (P-value &lt;0.05). Also, over time a significant decreasing trend in the viability of promastigotes confirmed the time-dependent manner of the fractions (P-value &lt;0.01). Furthermore, F5 had the highest leishmanicidal activity at the first incubation time compared with other fractions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Terpenoid-rich fractions of the\n                      <jats:italic toggle=\"yes\">P. abrotanoides<\/jats:italic>\n                      have a leishmanicidal activity that depends on time and concentration. Among them, F5 has the highest potency that may contain potent terpenoid constituents.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_175_21","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T02:18:03Z","timestamp":1698373083000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["In Vitro Study of the Leishmanicidal Activity of Perovskia Abrotanoides Terpenoid-Rich Fractions Against Leishmania Major (MRHO\/IR\/75\/ER)"],"prefix":"10.4103","volume":"12","author":[{"given":"Masoud","family":"Sadeghi Dinani","sequence":"first","affiliation":[{"name":"Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed A.","family":"Emarati Noushabadi","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Namdar","sequence":"additional","affiliation":[{"name":"Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Hassani Abharian","sequence":"additional","affiliation":[{"name":"Skin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Hejazi","sequence":"additional","affiliation":[{"name":"Skin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sebghatollahi","sequence":"additional","affiliation":[{"name":"Skin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3]]},"reference":[{"key":"R1-20240830","first-page":"37","article-title":"An overview on the therapeutics of neglected infectious diseases\u2014leishmaniasis and chagas diseases","volume":"9","author":"Chanda","year":"2021","journal-title":"Front Chem"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"e0006046","DOI":"10.1371\/journal.pntd.0006046","article-title":"Histoplasmosis in Africa: An emerging or a neglected disease?","volume":"12","author":"Oladele","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.amsu.2017.12.014","article-title":"A decade bibliometric analysis of global research on leishmaniasis in web of science database","volume":"26","author":"Soosaraei","year":"2018","journal-title":"Ann Med Surg"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40475-017-0099-1","article-title":"The leishmaniases of the mediterranean region","volume":"4","author":"Gradoni","year":"2017","journal-title":"Curr Trop Med Rep"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: A 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13071-017-1969-z","article-title":"Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India","volume":"10","author":"Srivastava","year":"2017","journal-title":"Parasit Vectors"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"e00904","DOI":"10.1128\/AAC.00904-19","article-title":"Genomic and metabolomic polymorphism among experimentally selected paromomycin-resistant leishmania donovani strains","volume":"64","author":"Shaw","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"e0005649","DOI":"10.1371\/journal.pntd.0005649","article-title":"Sterol 14\u03b1-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana","volume":"11","author":"Mwenechanya","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pt.2019.10.005","article-title":"New strategies and biomarkers for the control of visceral leishmaniasis","volume":"36","author":"Ibarra-Meneses","year":"2020","journal-title":"Trends Parasitol"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3389\/fphar.2021.690432","article-title":"The potential of traditional knowledge to develop effective medicines for the treatment of leishmaniasis","volume":"12","author":"Passero","year":"2021","journal-title":"Front Pharmacol"},{"key":"R11-20240830","first-page":"2050","article-title":"A review of treatments for leishmaniasis wound using the prescriptions of traditional medicine","volume":"8","author":"Parsaei","year":"2017","journal-title":"Int J Adv Biotechnol Res"},{"key":"R12-20240830","first-page":"1330","article-title":"A review of the most important native medicinal plants of Iran effective on leishmaniasis according to Iranian ethnobotanical references","volume":"8","author":"Naserifar","year":"2017","journal-title":"Int J Adv Biotechnol Res"},{"key":"R13-20240830","first-page":"2388","article-title":"Iranian medicinal plants as antimicrobial agents","volume":"2021","author":"Mahboubi","year":"2021","journal-title":"J Microbiol Biotechnology and Food Sciences."},{"key":"R14-20240830","first-page":"299","article-title":"Evaluation of-leishmanicidal effect of Perovskia abrotanoides Karel root extract by in vitro leishmanicidal assay using promastigotes of Leishmania major","volume":"1","author":"Jaafari","year":"2007","journal-title":"Pharmacologyonline"},{"key":"R16-20240830","article-title":"Evaluation of different concentrations of imatinib on the viability of leishmania major: An in vitro study","volume":"8","author":"Moslehi","year":"2019","journal-title":"Adv Biomed Res"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.actatropica.2016.11.004","article-title":"Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to 2013","volume":"166","author":"Holakouie-Naieni","year":"2017","journal-title":"Acta Trop"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ced.14919","article-title":"Treatment options for leishmaniasis","volume":"47","author":"Pradhan","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"e13566","DOI":"10.1111\/dth.13566","article-title":"Overview of herbal and traditional remedies in the treatment of cutaneous leishmaniasis based on traditional Persian medicine","volume":"33","author":"Parvizi","year":"2020","journal-title":"Dermatol Ther"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2017.28","article-title":"Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance","volume":"2","author":"Stokes","year":"2017","journal-title":"Nature microbiology"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"taab065","DOI":"10.1093\/jtm\/taab065","article-title":"Efficacy and safety of Pentamidine isethionate for tegumentary and visceral human leishmaniasis: A systematic review","volume":"28","author":"Piccica","year":"2021","journal-title":"J Travel Med"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"e0174497","DOI":"10.1371\/journal.pone.0174497","article-title":"To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL)","volume":"12","author":"Rabi Das","year":"2017","journal-title":"PLoS One"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine\u2014a life-saving drug for leishmaniasis\u2014is unavailable to people who need it the most","volume":"3","author":"Sunyoto","year":"2018","journal-title":"BMJ Global Health"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4269\/ajtmh.16-0811","article-title":"Susceptibility to miltefosine in Brazilian clinical isolates of leishmania (viannia) braziliensis","volume":"96","author":"Espada","year":"2017","journal-title":"Am J Trop Med Hygiene"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/187152106776359020","article-title":"Advances in the chemotherapy of chagas disease","volume":"5","author":"Saigua Encalada","year":"2006","journal-title":"Anti-Infective Agents in Medicinal Chemistry"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"e2100336","DOI":"10.1002\/cbdv.202100336","article-title":"Exploring innovative leishmaniasis treatment: Drug targets from pre-clinical to clinical findings","volume":"18","author":"Santana","year":"2021","journal-title":"Chem Biodivers"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/B978-0-12-821100-7.00018-2","article-title":"Systems biology and bioinformatics approaches in leishmaniasis","author":"Rajkhowa","year":"2021","journal-title":"In Applications of Nanobiotechnology for Neglected Tropical Diseases"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"e0249628","DOI":"10.1371\/journal.pone.0249628","article-title":"Safety and efficacy of allylamines in the treatment of cutaneous and mucocutaneous leishmaniasis: A systematic review","volume":"16","author":"Bezemer","year":"2021","journal-title":"PloS One"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"e02676","DOI":"10.1128\/AAC.02676-20","article-title":"Effect of itraconazole-ezetimibe-miltefosine ternary therapy in murine visceral leishmaniasis","volume":"65","author":"Andrade-Neto","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"107291","DOI":"10.1016\/j.intimp.2020.107291","article-title":"Synergic effect of eugenol oleate with amphotericin B augments anti-leishmanial immune response in experimental visceral leishmaniasis in vitro and in vivo","volume":"91","author":"Kar","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2573-4555.1000271","article-title":"Ethnobotany of medicinal plants used to treat leishmaniasis in Ethiopia: A systematic review","volume":"7","author":"Aschale","year":"2018","journal-title":"J Tradit Med Clin Naturopat."},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.2174\/1385272821666170207103634","article-title":"Quinoline alkaloids against neglected tropical diseases","volume":"21","author":"Musiol","year":"2017","journal-title":"Curr Org Chem"},{"key":"R33-20240830","first-page":"53","article-title":"Essential oil quantity and quality of different plant organs from Perovskia abrotanoides Karel in natural habitat of North Khorasan province","volume":"40","author":"Pourhosseini","year":"2018","journal-title":"J Plant Productions (Agron Breed Hort)"},{"key":"R34-20240830","first-page":"141","article-title":"Natural products as a novel source for antileishmanial drug development. Pathogenesis, Treatment and Prevention of Leishmaniasis","author":"Gouri","year":"2021","journal-title":"Academic Press, Missouri State University, USA"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1080\/14786419.2019.1684280","article-title":"Perovskanol, a new sesquiterpenoid with an unprecedented skeleton from Perovskia abrotanoides","volume":"35","author":"Karimzadeh","year":"2021","journal-title":"Nat Prod Res"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/B978-0-444-64185-4.00007-1","article-title":"Plant Terpenoids as Lead Compounds Against Malaria and Leishmaniasis","author":"Duarte","year":"2019","journal-title":"Studies in Natural Products Chemistry, Lisbon, Portugal"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_175_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:09Z","timestamp":1787067729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_175_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_175_21","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2021-06-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}